Table 1

Baseline characteristics of the 81 subjects who completed the CFRDT trial

CFRD FH−
IGT
Total cohortInsulinRepaglinidePlaceboTotal cohortInsulinRepaglinidePlacebo
n6123221620749
n (% female)31 (51)*12 (52)11 (50)8 (50)5 (25)3 (43)0 (0)2 (22)
Age (years)28 ± 929 ± 226 ± 228 ± 328 ± 727 ± 229 ± 528 ± 2
BMI (kg/m2)21.3 ± 2.920.6 ± 0.621.3 ± 0.722.2 ± 0.622.0 ± 2.720.7 ± 0.722.9 ± 1.722.5 ± 0.9
% Fat-free mass79 ± 979 ± 280 ± 277 ± 280 ± 881 ± 379 ± 580 ± 3
FVC (% predicted)90 ± 2287 ± 490 ± 694 ± 488 ± 1779 ± 782 ± 1098 ± 4
FEV1 (% predicted)70 ± 2563 ± 571 ± 678 ± 569 ± 2161 ± 761 ± 1378 ± 6
NIH score83 ± 1380 ± 384 ± 388 ± 382 ± 1479 ± 674 ± 989 ± 2
A1C (%)6.1 ± 0.6*6.2 ± (0.1)6.2 ± 0.16.0 ± 0.15.5 ± 0.45.5 ± 0.35.6 ± 0.15.5 ± 0.1
  • Data for the CFRD FH− and IGT total cohorts are means ± SD; data by treatment group as means ± SEM. There were no significant differences across treatment groups for CFRD FH− or IGT.

  • *Total cohort CFRD FH− vs. IGT, P < 0.05.